Screener / SEC EDGAR /CIK 0001088856 /10-K filed Feb 24, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Corcept Therapeutics Inc CORT

Compare with peers Embed
FY2025 at a glance

Sales up 12.8%, free cash flow down to $141.8M

XBRL, from each 10-K
RevenueStatements
$761.4M from $675.0M in FY2024
FY2016FY2025
Net incomeStatements
$99.7M from $141.2M in FY2024
FY2016FY2025
Free cash flowStatements
$141.8M from $196.1M in FY2024
FY2016FY2025
EPS (diluted)Statements
$0.82 from $1.23 in FY2024
FY2016FY2025
Operating marginStatements
5.9% from 20.3% in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (39)
EPS (ttm)
1.33
Sales (ttm)
963.6M
Net income (ttm)
162.3M
Sales growth
+12.8%
EPS growth
-33.3%
Sales Q/Q
+64.0%
Free cash flow
194.6M
Gross margin
-
Oper. margin
11.5%
Net margin
16.8%
FCF margin
20.2%
R&D / sales
33.5%
Dividend
-
Debt/Eq
-
Curr. ratio
3.00
Cash
98.7M
Op. cash flow (ttm)
198.1M
EBITDA
45.9M
EBITDA margin
6.0%
Quick ratio
2.93
ROIC
8.1%
FCF after stock pay
57.3M
Oper. margin low 5y
5.9%
Tax rate
-49.9%
Stock pay / sales
11.1%
Shares out.
109.4M
Shares Y/Y
+5.7%
Book / share
7.62
Cash / share
0.90
Sales / share
8.81
Asset turnover
0.93
Inventory turns
1.01
Days sales out.
29
Sales 3Y CAGR
+23.7%
Sales 5Y CAGR
+16.6%
EPS 3Y CAGR
-2.0%
EPS 5Y CAGR
-0.7%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 761.4M +28.2% a year Net income 99.7M +32.1% a year
FY2016 revenue 81.3M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-19-001879 FY2016 net income 8.1M · NetIncomeLoss, 0001628280-19-001879 81.3M FY2016 FY2017 revenue 159.2M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-20-002122 FY2017 net income 129.1M · NetIncomeLoss, 0001628280-20-002122 159.2M FY2017 FY2018 revenue 251.2M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-21-002861 FY2018 net income 75.4M · NetIncomeLoss, 0001628280-21-002861 251.2M FY2018 FY2019 revenue 306.5M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-22-002714 FY2019 net income 94.2M · NetIncomeLoss, 0001628280-22-002714 306.5M FY2019 FY2020 revenue 353.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-23-005581 FY2020 net income 106.0M · NetIncomeLoss, 0001628280-23-005581 353.9M FY2020 FY2021 revenue 366.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-24-005055 FY2021 net income 112.5M · NetIncomeLoss, 0001628280-24-005055 366.0M FY2021 FY2022 revenue 401.9M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-25-008167 FY2022 net income 101.4M · NetIncomeLoss, 0001628280-25-008167 401.9M FY2022 FY2023 revenue 482.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-26-011091 FY2023 net income 106.1M · NetIncomeLoss, 0001628280-26-011091 482.4M FY2023 FY2024 revenue 675.0M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-26-011091 FY2024 net income 141.2M · NetIncomeLoss, 0001628280-26-011091 675.0M FY2024 FY2025 revenue 761.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-26-011091 FY2025 net income 99.7M · NetIncomeLoss, 0001628280-26-011091 761.4M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (9 years).

From the same starting line, FY2016 to FY2025

Revenue, net income and free cash flow, each set to 100 in FY2016. What happened, from the 10-Ks. Not a forecast.

FY2016 = 100
500 1000 1500 100 Revenue: $81.3M in FY2016, $761.4M in FY2025 REVENUE $761.4M · 9.4x Net income: $8.1M in FY2016, $99.7M in FY2025 NET INCOME $99.7M · 12.2x Free cash flow: $18.2M in FY2016, $141.8M in FY2025 FREE CASH FLOW $141.8M · 7.8x FY2016 = 100FY2021FY2025
Revenue 9.4x $81.3M to $761.4M
Net income 12.2x $8.1M to $99.7M
Free cash flow 7.8x $18.2M to $141.8M

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Earnings per share +31.4% a year FY2016 $0.07 to FY2025 $0.82, 9 years
Book value per share +41.1% a year FY2015 $0.17 to FY2025 $5.40, 10 years
Free cash flow per share +44.8% a year FY2015 $0.03 to FY2025 $1.18, 10 years
0 2000 4000 6000 100 Book value / share: $0.17 in FY2015, $5.40 in FY2025 BOOK VALUE / SHARE $5.40 · 31.2x FCF / share: $0.03 in FY2015, $1.18 in FY2025 FCF / SHARE $1.18 · 40.6x FY2015 = 100FY2020FY2025

Each line is set to 100 in FY2015, so a line at 200 has doubled. What was filed, not a forecast. A line is left out when it is not above zero in every year.

Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $0.82$5.40$1.18
Dec 31, 2024 $1.23$5.99$1.73
Dec 31, 2023 $0.94$4.53$1.13
Dec 31, 2022 $0.87$4.33$1.03
Dec 31, 2021 $0.89$2.98$1.33
Dec 31, 2020 $0.85$4.21$1.21
Dec 31, 2019 $0.77$3.03$1.10
Dec 31, 2018 $0.60$2.18$0.91
Dec 31, 2017 $1.04$1.53$0.49
Dec 31, 2016 $0.07$0.36$0.16
Dec 31, 2015 -$0.06$0.17$0.03

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $485.5M
  • − All liabilities $188.8M
  • = Net current asset value $296.6M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $647.8M
  • = Tangible book value $647.8M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

CORT against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+12.8%64th of 155 · median +10.5%
Net margin
-4.1%15.3%
16.8%35th of 154 · median 6.8%
Return on equity
-5.2%18.5%
19.5%33rd of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
20.2%33rd of 145 · median 10.0%
CORT and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
CORT Corcept Therapeutics Inc$963.6M +12.8%-16.8%19.5%20.2%-
BCRX Biocryst Pharmaceuticals Inc$961.5M +94.1%97.8%-37.4%-38.0%-
IONS Ionis Pharmaceuticals Inc$960.1M +33.8%--56.9%-138.8%-64.2%4.60
BBIO BridgeBio Pharma, Inc.$945.5M +126%94.3%-62.6%--39.1%-
WRBY Warby Parker Inc.$934.7M +13.0%54.7%0.8%1.9%2.3%-
TGTX TG Therapeutics, Inc.$897.8M +87.3%82.7%11.8%18.5%9.5%1.30
All 162 companies in the group

Where each dollar goes

Revenue through the costs to the net profit, from the 10-K income statement

From $366.0M of sales to $112.5M of profit FY2021

Revenue to Gross profit: $360.7MRevenue to Cost of revenue: $5.3MGross profit to Operating profit: $124.5MGross profit to Operating expenses: $236.2MOperating profit to Net profit: $112.5MOperating profit to Tax & other: $12.0MOperating expenses to R&D: $113.9MOperating expenses to SG&A: $122.4M Revenue: $366.0M REVENUE $366.0M +3% Y/Y Gross profit: $360.7M · 99% margin GROSS PROFIT $360.7M 99% margin Cost of revenue: $5.3M · 1% of revenue COST OF REVENUE $5.3M 1% of revenue Operating profit: $124.5M · 34% margin OPERATING PROFIT $124.5M 34% margin · −3% Y/Y Operating expenses: $236.2M · 65% of revenue OPERATING EXPENSES $236.2M 65% of revenue Net profit: $112.5M · 31% margin NET PROFIT $112.5M 31% margin · +6% Y/Y Tax & other: $12.0M · 3% of revenue TAX & OTHER $12.0M 3% of revenue R&D: $113.9M · 31% of revenue R&D $113.9M 31% of revenue SG&A: $122.4M · 33% of revenue SG&A $122.4M 33% of revenue

From $401.9M of sales to $101.4M of profit FY2022

Revenue to Gross profit: $396.5MRevenue to Cost of revenue: $5.4MGross profit to Operating profit: $112.6MGross profit to Operating expenses: $283.8MOperating profit to Net profit: $101.4MOperating profit to Tax & other: $11.2MOperating expenses to R&D: $131.0MOperating expenses to SG&A: $152.8M Revenue: $401.9M REVENUE $401.9M +10% Y/Y Gross profit: $396.5M · 99% margin GROSS PROFIT $396.5M 99% margin Cost of revenue: $5.4M · 1% of revenue COST OF REVENUE $5.4M 1% of revenue Operating profit: $112.6M · 28% margin OPERATING PROFIT $112.6M 28% margin · −10% Y/Y Operating expenses: $283.8M · 71% of revenue OPERATING EXPENSES $283.8M 71% of revenue Net profit: $101.4M · 25% margin NET PROFIT $101.4M 25% margin · −10% Y/Y Tax & other: $11.2M · 3% of revenue TAX & OTHER $11.2M 3% of revenue R&D: $131.0M · 33% of revenue R&D $131.0M 33% of revenue SG&A: $152.8M · 38% of revenue SG&A $152.8M 38% of revenue

From $482.4M of sales to $106.1M of profit FY2023

Revenue to Gross profit: $475.9MRevenue to Cost of revenue: $6.5MGross profit to Operating profit: $107.3MGross profit to Operating expenses: $368.6MOperating profit to Net profit: $88.9MOperating profit to Tax: $18.4MOther income to Net profit: $17.3MOperating expenses to R&D: $184.4MOperating expenses to SG&A: $184.3M Revenue: $482.4M REVENUE $482.4M +20% Y/Y Gross profit: $475.9M · 99% margin GROSS PROFIT $475.9M 99% margin Cost of revenue: $6.5M · 1% of revenue COST OF REVENUE $6.5M 1% of revenue Operating profit: $107.3M · 22% margin OPERATING PROFIT $107.3M 22% margin · −5% Y/Y Other income: $17.3M · 4% of revenue OTHER INCOME $17.3M 4% of revenue Operating expenses: $368.6M · 76% of revenue OPERATING EXPENSES $368.6M 76% of revenue Net profit: $106.1M · 22% margin NET PROFIT $106.1M 22% margin · +5% Y/Y Tax: $18.4M · 4% of revenue TAX $18.4M 4% of revenue R&D: $184.4M · 38% of revenue R&D $184.4M 38% of revenue SG&A: $184.3M · 38% of revenue SG&A $184.3M 38% of revenue

From $675.0M of sales to $141.2M of profit FY2024

Revenue to Gross profit: $664.2MRevenue to Cost of revenue: $10.9MGross profit to Operating profit: $137.0MGross profit to Operating expenses: $527.2MOperating profit to Net profit: $116.7MOperating profit to Tax: $20.3MOther income to Net profit: $24.5MOperating expenses to R&D: $246.9MOperating expenses to SG&A: $280.3M Revenue: $675.0M REVENUE $675.0M +40% Y/Y Gross profit: $664.2M · 98% margin GROSS PROFIT $664.2M 98% margin Cost of revenue: $10.9M · 2% of revenue COST OF REVENUE $10.9M 2% of revenue Operating profit: $137.0M · 20% margin OPERATING PROFIT $137.0M 20% margin · +28% Y/Y Other income: $24.5M · 4% of revenue OTHER INCOME $24.5M 4% of revenue Operating expenses: $527.2M · 78% of revenue OPERATING EXPENSES $527.2M 78% of revenue Net profit: $141.2M · 21% margin NET PROFIT $141.2M 21% margin · +33% Y/Y Tax: $20.3M · 3% of revenue TAX $20.3M 3% of revenue R&D: $246.9M · 37% of revenue R&D $246.9M 37% of revenue SG&A: $280.3M · 42% of revenue SG&A $280.3M 42% of revenue

From $761.4M of sales to $99.7M of profit FY2025

Revenue to Gross profit: $748.4MRevenue to Cost of revenue: $13.0MGross profit to Operating profit: $44.8MGross profit to Operating expenses: $703.6MOperating profit to Net profit: $44.8MOther income to Net profit: $54.9MOperating expenses to R&D: $254.9MOperating expenses to SG&A: $448.7M Revenue: $761.4M REVENUE $761.4M +13% Y/Y Gross profit: $748.4M · 98% margin GROSS PROFIT $748.4M 98% margin Cost of revenue: $13.0M · 2% of revenue COST OF REVENUE $13.0M 2% of revenue Operating profit: $44.8M · 6% margin OPERATING PROFIT $44.8M 6% margin · −67% Y/Y Other income: $54.9M · 7% of revenue OTHER INCOME $54.9M 7% of revenue Operating expenses: $703.6M · 92% of revenue OPERATING EXPENSES $703.6M 92% of revenue Net profit: $99.7M · 13% margin NET PROFIT $99.7M 13% margin · −29% Y/Y R&D: $254.9M · 33% of revenue R&D $254.9M 33% of revenue SG&A: $448.7M · 59% of revenue SG&A $448.7M 59% of revenue

Where each $100 of sales went

FY2021
FY2022
FY2023
FY2024
FY2025
  • Cost of revenue
  • R&D
  • Costs, tax, other
  • Tax, less other income
  • Net profit

Band widths are the money. Gross profit is revenue less cost of revenue; operating expenses are gross profit less operating profit; R&D is from the income statement and the rest of the operating expenses is everything else; tax includes interest and other items when they are small. Y/Y is the change from the fiscal year before. Revenue by part only for the years in the last two 10-Ks' segment tables. The full income statement

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity 15.4% FY2020: 20.3% net income ÷ equity
Net margin 13.1% FY2020: 30.0% profit per $ of sales: 99.7M ÷ 761.4M
Asset turnover 0.91× FY2020: 0.62× sales per $ of assets: 761.4M ÷ 836.7M
Leverage 1.29× FY2020: 1.09× assets per $ of equity: 836.7M ÷ 647.8M

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin above the peer median
    16.8% vs 6.8%
  • Return on equity above 15%
    19.5%
  • A profit in every one of 10 years
Net margin, FY2016 to FY2025: 10.0% to 13.1%

Cash and shareholders

  • Free cash flow positive in every one of 10 years
    $141.8M last year
  • Share count down over 5 years
    −3.4%
  • Cash from operations above net income
    $142.0M vs $99.7M
Free cash flow, FY2016 to FY2025: 18.2M to 141.8M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

CORT's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue761.4M
FY2016: 81.3MFY2017: 159.2MFY2018: 251.2MFY2019: 306.5MFY2020: 353.9MFY2021: 366.0MFY2022: 401.9MFY2023: 482.4MFY2024: 675.0MFY2025: 761.4M FY2017FY2019FY2021FY2023FY2025
Net income99.7M
FY2016: 8.1MFY2017: 129.1MFY2018: 75.4MFY2019: 94.2MFY2020: 106.0MFY2021: 112.5MFY2022: 101.4MFY2023: 106.1MFY2024: 141.2MFY2025: 99.7M FY2017FY2019FY2021FY2023FY2025
Free cash flow141.8M
FY2016: 18.2MFY2017: 60.5MFY2018: 115.4MFY2019: 135.0MFY2020: 150.7MFY2021: 167.4MFY2022: 119.9MFY2023: 126.5MFY2024: 196.1MFY2025: 141.8M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay57.3M
FY2016: 11.1MFY2017: 47.2MFY2018: 91.6MFY2019: 105.7MFY2020: 117.2MFY2021: 124.5MFY2022: 77.5MFY2023: 77.6MFY2024: 134.8MFY2025: 57.3M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)0.82
FY2016: 0.07FY2017: 1.04FY2018: 0.60FY2019: 0.77FY2020: 0.85FY2021: 0.89FY2022: 0.87FY2023: 0.94FY2024: 1.23FY2025: 0.82 FY2017FY2019FY2021FY2023FY2025
Diluted shares120.0M
FY2016: 116.1MFY2017: 124.5MFY2018: 126.7MFY2019: 122.6MFY2020: 124.2MFY2021: 126.0MFY2022: 116.0MFY2023: 111.7MFY2024: 113.5MFY2025: 120.0M FY2017FY2019FY2021FY2023FY2025

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue81.3M159.2M251.2M306.5M353.9M366.0M401.9M482.4M675.0M761.4M
Cost of revenue2.1M3.6M5.2M5.5M5.6M5.3M5.4M6.5M10.9M13.0M
R&D23.8M40.4M75.2M89.0M114.8M113.9M131.0M184.4M246.9M254.9M
SG&A45.2M62.4M81.3M100.4M105.3M122.4M152.8M184.3M280.3M448.7M
Operating income10.2M52.9M89.5M111.6M128.2M124.5M112.6M107.3M137.0M44.8M
Pretax income8.1M52.8M92.2M116.7M131.6M125.0M116.2M124.6M161.5M66.5M
Income tax0-76.3M16.7M22.5M25.6M12.5M14.8M18.4M20.3M-33.2M
Net income8.1M129.1M75.4M94.2M106.0M112.5M101.4M106.1M141.2M99.7M
EPS (diluted)0.071.040.600.770.850.890.870.941.230.82
Diluted shares116.1M124.5M126.7M122.6M124.2M126.0M116.0M111.7M113.5M120.0M
Depreciation & amortization87K106K236K703K525K1.1M1.3M1.0M795K1.1M
EBITDA10.3M53.0M89.7M112.3M128.7M125.5M113.9M108.3M137.7M45.9M
Operating margin12.5%33.2%35.6%36.4%36.2%34.0%28.0%22.2%20.3%5.9%
Net margin10.0%81.1%30.0%30.7%30.0%30.7%25.2%22.0%20.9%13.1%
Revenue growth+61.7%+95.8%+57.8%+22.0%+15.5%+3.4%+9.8%+20.0%+39.9%+12.8%
EPS growth-+1386%-42.3%+28.3%+10.4%+4.7%-2.2%+8.0%+30.9%-33.3%

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow18.4M60.9M115.7M136.1M152.0M167.9M120.3M126.7M198.3M142.0M
Capital spending194K419K298K1.1M1.2M469K413K139K2.2M211K
Free cash flow18.2M60.5M115.4M135.0M150.7M167.4M119.9M126.5M196.1M141.8M
Stock-based pay (added back)7.1M13.4M23.7M29.3M33.5M42.9M42.4M48.9M61.4M84.5M
Free cash flow after stock pay11.1M47.2M91.6M105.7M117.2M124.5M77.5M77.6M134.8M57.3M
Buybacks0023.7M31.0M9.9M-0015.7M172.9M
Debt repaid14.8M15.1M00------
Investing cash flow-194K-73.5M-90.8M-117.8M-119.3M136.1M-114.3M90.9M-177.6M69.8M
Financing cash flow-7.1M-8.0M-14.3M-28.6M12.2M-302.6M-17.3M-148.7M-28.3M-220.4M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)7.1M13.4M23.7M29.3M33.5M42.9M42.4M48.9M61.4M84.5M
Stock-based pay / revenue8.7%8.4%9.5%9.6%9.5%11.7%10.6%10.1%9.1%11.1%
Operating lease cash paid---1.6M1.8M2.1M2.3M2.4M1.4M1.4M
Right-of-use assets---3.4M2.5M514K1.1M120K5.3M4.6M
Operating lease liabilities---3.5M2.6M526K1.1M151K6.9M6.1M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CORT/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.